All posts by PIER MARIA FORNASARI

JAMA published large study provides deeper insight into long COVID symptoms

NIH-funded research effort identifies most common symptoms, potential subgroups, and initial symptom-based scoring system – with aim of improving future diagnostics and treatment. Initial findings from a study of nearly 10,000 Americans, many of whom had COVID-19, have uncovered new details about long COVID, the post-infection set of conditions that can affect nearly every tissue

Read More


Study reveals novel action mechanism of corticosteroids in combating inflammation caused by COVID-19

Since the start of the COVID-19 pandemic, a class of corticosteroids called glucocorticoids (GCs) have become established as one of the main treatment options, especially for severe cases, thanks to their anti-inflammatory and immunosuppressant action. Brazilian researchers recently discovered new ways in which these drugs influence the organism’s inflammatory response during an infection: they raise

Read More


NIH study identifies features of Long COVID neurological symptoms

Differences in Physiologic Variables in Patients With Postacute Sequelae of SARS-CoV-2 Infection (PASC, Red) Compared With Healthy Volunteers (HVs, Gray) Each dot represents 1 participant; bars represent standard errors of the mean (top edge of rectangle). p Values are for independent means t tests. (A) Heart rate (HR); (B) finger systolic blood pressure (BPs); (C) baroreflex-cardiovagal gain; (D) high-frequency

Read More


Study finds ChatGPT outperforms physicians in providing high-quality, empathetic advice to patient questions

In a new JAMA Internal Medicine study, independent licensed healthcare professionals evaluated both quality (left) and empathy (right) for ChatGPT and physician responses to patient questions, preferring ChatGPT’s responses 79% of the time. There has been widespread speculation about how advances in artificial intelligence (AI) assistants like ChatGPT could be used in medicine.  A new

Read More


New Build Better Bones online platform to support people with osteoporosis and their caregivers 

The new International Osteoporosis Foundation (IOF) platform provides easy-to-follow exercise guidance and nutritional tips to benefit bone health, alerts to falls safety hazards in the home, and provides helpful information for caregivers.  The International Osteoporosis Foundation (IOF) has launched the Build Better Bones platform, a new online resource that provides people with osteoporosis, and their caregivers, with

Read More


Machine learning links unresolving secondary pneumonia to mortality in COVID-19 patients with severe pneumonia.

Secondary bacterial pneumonia that does not resolve was a key driver of death in patients with Covid, according to a study. The study was published in the Journal of Clinical Investigation. The scientists also found evidence that Covid does not cause a “cytokine storm”, so often believed to cause death. Secondary bacterial pneumonia that does

Read More


FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene

Action FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based on a reduction in plasma neurofilament light (NfL), a blood-based

Read More


FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older

Read More